Published in Ann N Y Acad Sci on June 01, 2006
Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis (2008) 1.20
Can bone loss in rheumatoid arthritis be prevented? Osteoporos Int (2013) 1.02
Raman spectroscopy detects deterioration in biomechanical properties of bone in a glucocorticoid-treated mouse model of rheumatoid arthritis. J Biomed Opt (2011) 1.02
The role of the T cell in age-related inflammation. Age (Dordr) (2012) 1.00
Osteoporosis and gastrointestinal disease. Gastroenterol Hepatol (N Y) (2010) 0.99
Grape-seed proanthocyanidin extract as suppressors of bone destruction in inflammatory autoimmune arthritis. PLoS One (2012) 0.94
Bone remodelling markers in rheumatoid arthritis. Mediators Inflamm (2014) 0.92
Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int (2010) 0.89
Osteoimmunology: a brief introduction. Immune Netw (2013) 0.89
The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int (2010) 0.85
Loss of Bone and Wnt10b Expression in Male Type 1 Diabetic Mice Is Blocked by the Probiotic Lactobacillus reuteri. Endocrinology (2015) 0.85
Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. Arthritis Care Res (Hoboken) (2013) 0.85
Effects of anti-tumor necrosis factor α agents on bone. Curr Opin Rheumatol (2012) 0.84
The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. Arthritis Res Ther (2015) 0.83
Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res (2012) 0.83
Tumour necrosis factor blockade and the risk of osteoporosis: back to the future. Arthritis Res Ther (2007) 0.82
Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. Rheumatol Int (2011) 0.81
Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. Clin Rheumatol (2008) 0.81
Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn (2013) 0.80
Bone and TNF in rheumatoid arthritis: clinical implications. RMD Open (2015) 0.79
Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int (2016) 0.79
Association of periodontitis with rheumatoid arthritis and atherosclerosis: Novel paradigms in etiopathogeneses and management? Open Access Rheumatol (2010) 0.79
The correlation between phalangeal quantitative ultrasonography and dual energy x-ray absorptiometry in women with premature ovarian failure. Mcgill J Med (2008) 0.77
Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over. Osteoporos Int (2013) 0.76
Update on the use of etanercept across a spectrum of rheumatoid disorders. Biologics (2008) 0.76
Disease Activity and Bone Mineral Density of MCP Joints in Patients with Rheumatoid and Psoriatic Arthritis: Is There a Correlation?-A Study in Patients Treated with Methotrexate and an Anti-TNF α Agent. ISRN Rheumatol (2013) 0.76
Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease. Osteoporos Int (2012) 0.76
Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study. Rheumatol Int (2017) 0.75
Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis. Dis Markers (2015) 0.75
Prostaglandin E(2) binding peptide screened by phage displaying: a new therapeutic strategy in rheumatoid arthritis. Lipids Health Dis (2011) 0.75
Combined infliximab and methotrexate treatment improves the depressive state in rheumatoid arthritis patients more effectively than methotrexate alone. Eur J Rheumatol (2014) 0.75
Combined effects of infliximab and methotrexate on rheumatoid arthritis osteoblastic cell metabolism. Clin Exp Med (2014) 0.75
Skeletal complications of rheumatoid arthritis. Osteoporos Int (2017) 0.75
Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis. Clin Rheumatol (2007) 0.75
Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis (2010) 2.91
Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum (2002) 2.23
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum (2012) 2.23
Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther (2009) 1.87
The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol (2014) 1.87
Vitamin D in rheumatoid arthritis. Autoimmun Rev (2007) 1.78
Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum (2007) 1.78
Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol (2010) 1.78
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) (2009) 1.76
How psychological stress via hormones and nerve fibers may exacerbate rheumatoid arthritis. Arthritis Rheum (2005) 1.70
Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol (2010) 1.64
Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum (2008) 1.51
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. Ann Rheum Dis (2009) 1.48
Neuroendocrine immune mechanisms in rheumatic diseases. Trends Immunol (2002) 1.44
Estrogens and autoimmune diseases. Ann N Y Acad Sci (2006) 1.37
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci (2006) 1.32
Epidemiology of chronic musculoskeletal pain. Best Pract Res Clin Rheumatol (2011) 1.29
Capillaroscopy. Best Pract Res Clin Rheumatol (2008) 1.26
Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Ann N Y Acad Sci (2002) 1.25
Rheumatology education in Europe: results of a survey of young rheumatologists. Clin Exp Rheumatol (2011) 1.23
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum (2011) 1.15
Use of glucocorticoids and risk of infections. Autoimmun Rev (2008) 1.15
A growing need for capillaroscopy in rheumatology. Arthritis Rheum (2009) 1.11
Nailfold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis. J Rheumatol (2013) 1.10
How to perform and interpret capillaroscopy. Best Pract Res Clin Rheumatol (2013) 1.07
Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol (2009) 1.05
The contribution of capillaroscopy to the differential diagnosis of connective autoimmune diseases. Best Pract Res Clin Rheumatol (2007) 1.04
Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum (2004) 1.04
Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J Rheumatol (2003) 1.03
Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum (2010) 1.03
Circadian rhythms in rheumatology--a glucocorticoid perspective. Arthritis Res Ther (2014) 1.03
Estrogens in pregnancy and systemic lupus erythematosus. Ann N Y Acad Sci (2006) 1.02
Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6. J Rheumatol (2002) 1.02
Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. Ann Rheum Dis (2010) 1.02
Capillarosecopic patterns in rheumatic diseases. Acta Reumatol Port (2007) 1.02
Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol (2006) 1.01
Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line. Arthritis Res Ther (2005) 1.00
Capillaroscopy. Best Pract Res Clin Rheumatol (2005) 0.99
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol (2011) 0.99
Interspinous bursitis is common in polymyalgia rheumatica, but is not associated with spinal pain. Arthritis Res Ther (2014) 0.98
Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent? Ann Rheum Dis (2012) 0.98
Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? a pilot study. Ann Rheum Dis (2012) 0.98
Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev (2011) 0.98
Estrogen metabolism and autoimmunity. Autoimmun Rev (2011) 0.96
Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al. Arthritis Rheum (2007) 0.95
Circadian rhythms: glucocorticoids and arthritis. Ann N Y Acad Sci (2006) 0.95
Melatonin in rheumatoid arthritis: synovial macrophages show melatonin receptors. Ann N Y Acad Sci (2002) 0.94
High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography. Rheumatology (Oxford) (2013) 0.94
Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol (2014) 0.93
Sex hormones and rheumatoid arthritis. Autoimmun Rev (2002) 0.93
More night than day--circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J Rheumatol (2010) 0.93
Effects of testosterone, 17beta-estradiol, and downstream estrogens on cytokine secretion from human leukocytes in the presence and absence of cortisol. Ann N Y Acad Sci (2006) 0.93
Anti-inflammatory cooperativity of corticosteroids and norepinephrine in rheumatoid arthritis synovial tissue in vivo and in vitro. FASEB J (2002) 0.93
Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action. Arthritis Rheum (2006) 0.93
The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008. Isr Med Assoc J (2008) 0.92
CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res Ther (2009) 0.92
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev (2010) 0.92
Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study. Arthritis Care Res (Hoboken) (2010) 0.92
Effects of estrogens on extracellular matrix synthesis in cultures of human normal and scleroderma skin fibroblasts. Ann N Y Acad Sci (2010) 0.91
Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. Ann Rheum Dis (2008) 0.91
Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases--the 10-year update. Semin Arthritis Rheum (2013) 0.91
Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol (2012) 0.90
Vitamin D, steroid hormones, and autoimmunity. Ann N Y Acad Sci (2014) 0.90
Peritoneal fluid macrophages in endometriosis: correlation between the expression of estrogen receptors and inflammation. Fertil Steril (2007) 0.90
Peripheral blood perfusion correlates with microvascular abnormalities in systemic sclerosis: a laser-Doppler and nailfold videocapillaroscopy study. J Rheumatol (2010) 0.90
Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol (2011) 0.90
Timing of transition between capillaroscopic patterns in systemic sclerosis. Arthritis Rheum (2012) 0.90
Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheumatol (2008) 0.89
Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol (2013) 0.88
Synovial fluid estrogens in rheumatoid arthritis. Autoimmun Rev (2004) 0.87
Androgens in rheumatoid arthritis: when are they effectors? Arthritis Res Ther (2009) 0.87
Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol (2007) 0.87
Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis. Clin Rheumatol (2007) 0.87
Further evidence for insufficient hypothalamic-pituitary-glandular axes in polymyalgia rheumatica. J Rheumatol (2006) 0.87
Indoleamine 2,3 dioxygenase gene polymorphisms correlate with CD8+ Treg impairment in systemic sclerosis. Hum Immunol (2012) 0.86
Nailfold capillaroscopy in systemic sclerosis: data from the EULAR scleroderma trials and research (EUSTAR) database. Microvasc Res (2013) 0.86
The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Clin Exp Rheumatol (2014) 0.86